ImmunityBio News

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

BenzingaFeb 14 07:53 ET

ImmunityBio Analyst Ratings

BenzingaFeb 14 07:52 ET

BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $6

Moomoo NewsFeb 3 08:31 ET

ImmunityBio Analyst Ratings

BenzingaJan 27 09:58 ET

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

BenzingaJan 27 09:58 ET

ImmunityBio Price Target Maintained With a $30.00/Share by D. Boral Capital

Dow JonesJan 16 07:38 ET

ImmunityBio Analyst Ratings

BenzingaJan 16 07:28 ET

ImmunityBio Initiated at Buy by BTIG

Dow JonesJan 10 13:33 ET

BTIG Initiates ImmunityBio at Buy With $6 Price Target

MT NewswiresJan 10 10:27 ET

BTIG Initiates ImmunityBio(IBRX.US) With Buy Rating, Announces Target Price $6

Moomoo NewsJan 10 07:34 ET

ImmunityBio Analyst Ratings

BenzingaDec 20, 2024 10:02 ET

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

BenzingaDec 20, 2024 10:01 ET

ImmunityBio Analyst Ratings

BenzingaNov 19, 2024 12:32 ET

ImmunityBio Analyst Ratings

BenzingaNov 12, 2024 12:06 ET

IBRX Soars 47% on Initial Trials For Cell Therapy Product

Barron'sOct 25, 2024 13:58 ET

EF Hutton Initiates ImmunityBio(IBRX.US) With Buy Rating, Announces Target Price $30

Moomoo NewsOct 23, 2024 08:35 ET

EF Hutton Initiates Coverage On ImmunityBio With Buy Rating, Announces Price Target of $30

BenzingaOct 23, 2024 07:12 ET

ImmunityBio Analyst Ratings

BenzingaAug 19, 2024 12:29 ET

Jefferies Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $8

Moomoo NewsAug 19, 2024 08:33 ET

Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), ImmunityBio (IBRX) and Neurocrine (NBIX)

TipRanksAug 19, 2024 08:15 ET